{"version":"1.0","provider_name":"FYB Financial Yearbook","provider_url":"https:\/\/www.fyb.de\/en\/","author_name":"Tatjana Anderer","author_url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/","title":"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jZmjtNoPKU\"><a href=\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\">Series B: ImCheck Therapeutics receives USD 53 million<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/embed\/#?secret=jZmjtNoPKU\" width=\"600\" height=\"338\" title=\"&#8220;Series B: ImCheck Therapeutics receives USD 53 million&#8221; &#8212; FYB Financial Yearbook\" data-secret=\"jZmjtNoPKU\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","thumbnail_width":1000,"thumbnail_height":701,"description":"Antwerp (BE) \/ Marseille (FR) \u2014 In a Series B finan\u00adcing round tota\u00adling $53 million, Gimv has increased its stake in ImCheck Thera\u00adpeu\u00adtics, an emer\u00adging provi\u00adder of onco\u00adlogy and auto\u00adim\u00admune therapy solu\u00adti\u00adons based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new inves\u00adtors. In addi\u00adtion [&hellip;]"}